Advertisement

Digestive Diseases and Sciences

, Volume 54, Issue 10, pp 2298–2299 | Cite as

Is Furazolidone Therapy for Helicobacter pylori Effective and Safe?

  • Vincenzo De Francesco
  • Enzo Ierardi
  • Cesare Hassan
  • Angelo Zullo
Correspondence

We have read with great interest the study performed in Pakistan by Abbas et al. [1] on the efficacy and safety of a “rescue” therapy to cure Helicobacter pylori infection. Briefly, following a quadruple therapy including high-dose esomeprazole, bismuth salts, amoxicillin-clavulanic acid, and furazolidone, an 81% eradication rate was achieved at ITT analysis, with a side-effects incidence as high as 50%. The authors concluded that “it is reasonably well tolerated and is an effective second-line regimen” and even suggested it could be used as a first-line therapy. We have some concerns about these conclusions. First, following the first-line therapy, H. pylorieradication was achieved in 119 (67.6%) out of 176 enrolled patients. Consequently, 57 eradication failure patients were available instead of 52, as was reported. If all these patients received a second-line therapy, then both ITT and PP analysis should be accordingly calculated. Second, the reported side-effects incidence (up to...

Keywords

Bismuth Proton Pump Inhibitor Pylorus Infection Triple Therapy Esomeprazole 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Abbas Z, Yakoob J, Abid S, et al. Furazolidone, co-amoxiclav, colloidal bismuth subcitrate, and esomeprazole for patients who failed to eradicate Helicobacter pylori with triple therapy. Dig Dis Sci. 2008 Dec 5 (Epub ahead of print).Google Scholar
  2. 2.
    Gisbert JP, De La Morena F. Systematic review and meta-analysis: levofloxacin-based rescue regimens after Helicobacter pylori treatment failure. Aliment Pharmacol Ther. 2006;23:35–44. doi: 10.1111/j.1365-2036.2006.02737.x.PubMedCrossRefGoogle Scholar
  3. 3.
    Gisbert JP, Pajares JM. Esomeprazole-based therapy in Helicobacter pylori eradication: a meta-analysis. Dig Liver Dis. 2004;36:253–259. doi: 10.1016/j.dld.2003.12.010.PubMedCrossRefGoogle Scholar
  4. 4.
    Phillips RH, Whitehead MW, Doig LA, et al. Is eradication of Helicobacter pylori with colloidal bismuth subcitrate quadruple therapy safe? Helicobacter. 2001;6:151–156. doi: 10.1046/j.1523-5378.2001.00022.x.PubMedCrossRefGoogle Scholar
  5. 5.
    Tatsuta M, Iishi H, Baba M, Taniguchi H. Attenuating effect of the monoamine oxidase inhibitor furazolidone on the anti-carcinogenetic effect of cysteamine on gastric carcinogenesis induced by N-methyl-N′-nitro-N-nitrosoguanidine in Wistar rats. Int J Cancer. 1991;48:605–608. doi: 10.1002/ijc.2910480420.PubMedCrossRefGoogle Scholar
  6. 6.
    Ahmed HH, El-Aziem SH, Abdel-Wahhab MA. Potential role of cysteine and methionine in the protection against hormonal imbalance and mutagenicity induced by furazolidone in female rats. Toxicology. 2008;243:31–42. doi: 10.1016/j.tox.2007.09.018.PubMedCrossRefGoogle Scholar
  7. 7.
    Felga GE, Silva FM, Barbuti RC, Navarro-Rodriguez T, Zaterka S, Eisig JN. Quadruple therapy with furazolidone for retreatment in patients with peptic ulcer disease. World J Gastroenterol. 2008;14:6224–6227.PubMedCrossRefGoogle Scholar
  8. 8.
    Taghavi SA, Jafari A, Eshraghian A. Efficacy of a new therapeutic regimen versus two routinely prescribed treatments for eradication of Helicobacter pylori: a randomized, double-blind study of doxycycline, co-Amoxiclav, and omeprazole in Iranian Patients. Dig Dis Sci. 2009;54(3):599–603 Jul 2 (Epub ahead of print).Google Scholar
  9. 9.
    Buzás GM, Józan J. Nitrofuran-based regimens for the eradication of Helicobacter pylori infection. J Gastroenterol Hepatol. 2007;22:1571–1581.PubMedCrossRefGoogle Scholar
  10. 10.
    Dobiás L, Cerná M, Rössner P, Srám R. Genotoxicity and carcinogenicity of metronidazole. Mutat Res. 1994;317:177–194.PubMedGoogle Scholar
  11. 11.
    Park BC, Park SY, Lee JS, Mousa SA, Kim JT, Kwak MK, Kang KW, Lee ES, Choi HG, Yong CS, Kim JA. The anti-angiogenic effects of 1-furan-2-yl-3-pyridin-2-yl-propenone are mediated through the suppression of both VEGF production and VEGF-induced signaling. Vascul Pharmacol 2009;50(3-4):123–131 Nov 28 (Epub ahead of print).Google Scholar
  12. 12.
    Lee KI, Park Y, Park SJ, et al. Naphthofuroquinone derivatives: inhibition of receptor tyrosine kinases. Bioorg Med Chem Lett. 2006;16:737–742.PubMedCrossRefGoogle Scholar
  13. 13.
    Ford AC, Malfertheiner P, Giguere M, Santana J, Khan M, Moayyedi P. Adverse events with bismuth salts for Helicobacter pylori eradication: systematic review and meta-analysis. World J Gastroenterol. 2008;14:7361–7370.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  • Vincenzo De Francesco
    • 1
  • Enzo Ierardi
    • 1
  • Cesare Hassan
    • 2
  • Angelo Zullo
    • 2
  1. 1.Gastroenterology Unit“Riuniti” HospitalFoggiaItaly
  2. 2.Gastroenterology and Digestive EndoscopyNuovo Regina Margherita HospitalRomeItaly

Personalised recommendations